From Our Partners
Saturday, July 2, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

MAPP Biopharmaceutical Awarded Funding for Ebola Drug

by Global Biodefense Staff
July 30, 2014
MAPP Biopharmaceutical Awarded Funding for Ebola Drug

The Defense Threat Reduction Agency (DTRA) has announced intentions to award a sole source modification to current contract HDTRA1-13-C-0018 to MAPP Biopharmaceutical in support of Ebola countermeasures.

The award is a follow-on to a current contract which focuses on development of a monoclonal antibody cocktail for Ebola Zaire. The proposed work comprises specific, additional tasks which are justified by the promising results from the work already conducted under the current contract.

The additional funding will be used to prepare and submit an Investigational New Drug (IND) application package to the Food and Drug Administration (FDA) for ZMappTM and to provide sufficient quantity of the therapeutic to perform a Phase 1 clinical safety study.

These additional tasks will be performed within the current period of performance of 12 months. The work being added will be done so on a cost-plus fixed-fee basis

Source: FBO.gov

Editor’s Note: As Mapp’s products transition to clinical evaluation, ownership and development responsibilities are transferred to LeafBio, Mapp’s commercialization partner.

From Our Partners
Tags: AntiviralsDefense Threat Reduction AgencyEbola

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
Industry News

Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors

May 26, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC